Last reviewed · How we verify
rhFVIIa
At a glance
| Generic name | rhFVIIa |
|---|---|
| Also known as | Coagulation Factor VIIa (Recombinant) |
| Sponsor | rEVO Biologics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors (PHASE4)
- A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhFVIIa CI brief — competitive landscape report
- rhFVIIa updates RSS · CI watch RSS
- rEVO Biologics portfolio CI